Digital image analysis in pathology, exemplified in prostate cancer;Digital bildebehandling i patologifaget - Eksemplifisert ved cancer prostatae

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 4, 2000, Pages 479-488

  Danielsen, Håvard E ^a   Kildal, Wanja ^a   Sudbø, Jon ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

CANCER STAGING; CHROMATIN; DNA PROBE; FACTUAL DATABASE; FLOW CYTOMETRY; GENETICS; HUMAN; IMAGE ENHANCEMENT; IMAGE PROCESSING; IN SITU HYBRIDIZATION; MALE; METHODOLOGY; MORTALITY; PATHOLOGY; PLOIDY; PROGNOSIS; PROSTATE TUMOR; REVIEW;

CHROMATIN; DATABASES, FACTUAL; DNA PROBES; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION; MALE; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0034628230     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Chieco P, Derenzini M. The Feulgen reaction 75 years on. Histochem Cell Biol 1999; 111: 345-58.
2. Jeffers MD, Michie BA, Oakes SJ, Gillan JE. Comparison of ploidy analysis by flow cytometry and image analysis in hydatidiform mole and non-molar abortion. Histopathology 1995; 27: 415-21.
3. Bertino B, Knape WA, Pytlinska M, Strauss K, Hammou JC. A comparative study of DNA content as measured by flow cytometry and image analysis in 1864 specimens. Anal Cell Pathol 1994; 377-94.
4. Banks ER, Jennings CD, Jacobs S, Davey DD. Comparative assessment of DNA analysis in effusions by image analysis and flow cytometry. Diagn Cytopathol 1994; 62-6.
5. Spyratos F, Briffod M. DNA ploidy and S-phase fraction by image and flow cytometry in breast cancer fine-needle cytopunctures. Mod Pathol 1997; 556-63.
6. Epp RA, Justice WM, Garcia FU, McGregor DH, Giri SP, Kimler BF. Retrospective DNA ploidy analysis by image and flow cytometry in head and neck cancer. Laryngoscope 1996; 106: 1306-13.
7. Goulandris N, Karakitsos P, Georgoulakis J, Bellos C, Deliveliotis C, Legaki S. Deoxyribonucleic acid measurements in transitional cell carcinomas: comparison of flow and image cytometry techniques J Urol 1996; 156: 958-60.
8. Chen TL, Luo I, Mikhail N, Raskova J, Raska K jr. Comparison of flow and image cytometry for DNA content analysis of fresh and formalin-fixed, paraffin-embedded tissue in breast carcinoma. Cytometry 1995; 22: 181-9.
9. Bowman R, Kanacki ZA, Garberoglio C, Chase DR. Comparison between image and flow cytometry. A priori factors that influence technique. Anal Quant Cytol Histol 1995; 17: 276-83.
10. Berner A, Danielsen HE, Juul NO, Juul ME, Pettersen EO, Reith A et al. Caveats in the estimation of DNA-ploidy in paraffin embedded specimens of primary prostate cancer and lymph node metastases by flow and image cytometry. Anal Cell Pathol 1993; 5: 339-52.
11. Dawson AE, Norton JA, Weinberg DS. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 1990; 136: 1115-24.
12. Perotti D, Corletto V, Giardini R, Parafioriti A, Fossati BF, Luksch R. Retrospective analysis of ploidy in primary osseous and extraosseous Ewing family tumors in children. Tumori 1998; 84: 493-8.
13. Alanen KA, Lintu M, Joensuu H. Image cytometry of breast carcinomas that are DNA diploid by flow cytometry: time to revise the concept of DNA diploidy? Anal Quant Cytol Histol 1998; 20: 178-86.
14. Peiro G, Lerma E, Climent MA, Segui MA, Alonso MC, Prat J. Prognostic value of S-phase fraction in lymph-node-negative breast cancer by image and flow cytometric analysis. Mod Pathol 1997; 10: 216-22.
15. Carey FA, Gray E, O'Mahony M, Craig SR, Salto-Tellez M, Lamb D. A comparison of flow and image DNA cytometry in prediction of patient prognosis in surgically resected small cell lung cancer. Anal Cell Pathol 1996 12: 137-43.
16. Kilpatrick SE, Teot LA, Geisinger KR, Martin PL, Shumate DK, Zbieranski N et al. Relationship of DNA ploidy to histology and prognosis in rhabdomyosarcoma. Comparison of flow cytometry and image analysis. Cancer 1994; 74: 3227-33.
17. O'Meara A, Gururangan S, Ball R, Kay E, Kelsey A. Ploidy changes between diagnosis and relapse in childhood renal tumours. Urol Res 1993; 21: 345-7.
18. Tavares AS, Costa J, de Carvalho A, Reis M. Tumour ploidy and prognosis in carcinomas of the bladder and prostate. Br J Cancer 1966; 20: 438-41.
19. Tavares AS, Costa J, Maia JC. Correlation between ploidy and prognosis in prostate carcinoma. J Urol 1973; 109: 676-9.
20. Atkin NB, Kay R. Prognostic significance of modal DNA value and other factors in malignant tumours, based on 1465 cases. Br J Cancer 1979; 40: 210-21.
21. Caspersson T, Auer G, Fallenius A, Kudynowski J. Cytochemical changes in the nucleus during tumour development. Histochem J 1983; 15: 337-62.
22. Zetterberg A, Esposti P-L. Cytophotometric DNA analysis of aspirated cells from prostate carcinoma. Acta Cytol 1976; 20: 46-57.
23. Lieber MM, Cheng WS. The role of nuclear DNA ploidy in the prognosis and management of patients with prostate cancer. Compr Ther 1991; 17: 26-32.
24. Rainwater LM, Zincke H. Nuclear DNA ploidy and prostate cancer. Cancer Treat Res 1992; 59: 53-63.
25. Gee JMP. An update on the role of ploidy in prostate carcinoma. Henry Ford Hosp Med J 1992; 40: 99-102.
26. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 1993; 72: 3020-8.
27. Visakorpi T, Kallioniemi O-P, Koivula T, Isola J. New prognostic factors in prostatic carcinoma. Eur Urol 1993; 24: 438-49.
28. Hedlund PO, Esposti P, Falkmer U, Jacobsson H. DNA as a prognostic marker in advanced high-grade prostatic cancer. A preliminary report. SPCG-I study. Acta Oncol 1991; 30: 215-7.
29. Shankey TV, Kallioniemi OP, Koslowski JM, Lieber ML, Mayall BH, Miller G et al. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 1993; 14: 497-500.
30. Schroder F, Tribukait B, Bocking A, DeVere WR, Koss L, Lieber M et al. Clinical utility of cellular DNA measurements in prostate carcinoma. Scand J Urol Nephrol Suppl 1994; 162: 51-63.
31. Adolfsson J. Prognostic value of deoxyribonucleic acid content in prostate cancer: A review of current results. Int J Cancer 1994; 58: 211-6.
32. Tucci JS, Blumenfeld W, Narayan P. Ploidy status correlates with outcome in stage B prostate adenocarcinoma. Braz J Med Biol Res 1994; 27: 25-32.
33. Ross JS, Figge H, Bui HX, del Rosario AD, Jennings TA, Rifkin MD et al. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 1994; 74: 2811-8.
34. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 1994; 19: 249-58.
35. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 1994; 7: 835-41.
36. Lieber MM. Practical clinical utility of DNA ploidy for managing patients with prostate carcinoma. Urology 1995; 45: 558-62.
37. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995; 153: 1015-9.
38. Cheng L, Sebo TJ, Slezak J, Pisansky TM, Bergstralh EJ, Neumann RM et al. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer 1998; 83: 2164-71.
39. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman-RP J et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79: 2162-70.
40. Ross JS, Sheehan C, Ambros RA, Nazeer T, Jennings TA, Kaufman-RP J et al. Needle biopsi DNA ploidy status predicts grade shifting in Prostate Cancer. Am J Surg Pathol 1999; 23: 296-301.
41. Pignatelli D, Leitao D, Maia M, Schmidt F. DNA quantification and ploidy patterns in human adrenocortical neoplasms. Endocr Res 1998; 24: 869-74.
42. Coetzee LJ, Layfield LJ, Hars V, Paulson DF. Proliferative index determination in prostatic carcinoma tissue: Is there any additional prognostic value greater than that of gleason score, ploidy and pathological stage? J Urol 1997; 157: 214-8.
43. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23: 273-9.
44. Morris JA. Information and observer disagreement in histopathology. Histopathology 1994; 25: 123-8.
45. Fleming KA. Evidence-based pathology. J Pathol 1996; 179: 127-8.
46. McLean M, Srigley J, Banerjee D, Warde P, Hao Y. Interobserver variation in prostate cancer. Clin Oncol 1997; 9: 222-5.
47. Lessels AM, Burnett RA, Howatson SR, Lang S, Lee FD, McLaren KM et al. Observer variability in the histopathological reporting of needle biopsy specimens of the prostate. Hum Pathol 1997; 28: 646-9.
48. Wolffe A. Chromatin - structure and function. 3. utg. San Diego: Academic Press, 1998.
49. Schulerud H, Kristensen GB, Liestol K, Vlatkovic L, Reith A, Albregtsen F et al. A review of caveats in statistical nuclear image analysis. Anal Cell Pathol 1998; 16: 63-82.
50. Marchevsky AM, Gil J. Methods in laboratory investigations. Lab Invest 1986; 54: 708-16.
51. Liautaud-Roger F, Dufer J, Pluot M, Delisle MJ, Coninx P. Contribution of quantitative cytology to the cytological diagnosis of thyriod neoplasms. Anticancer Res 1989; 9: 231-4.
52. Becker RL, Mikel UV, O'Leary TJ. Morphometric distinction of sclerosing adenosis from tubular carcinoma of the breast. Pathol Res Pract 1992; 188: 847-51.
53. Unger PD, Watson CW, Liu Z, Gil J. Morphometric analysis of neoplastic renal aspirates and benign renal tissue. Anal Quant Cytol Histol 1993; 15: 61-6.
54. Yogesan K, Schulerud H, Albregtsen F, Danielsen HE. Ultrastructural texture analysis as a diagnostic tool in mouse liver carcinogenesis. Ultrastruct Pathol 1998; 22: 27-37.
55. Baak JP. The relative prognostic significance of nucleolar morphometry in invasive ductal breast cancer. Histopathology 1985; 9: 437-44.
56. Van der Poel HG, Boon ME, Kok LP, van der Meulen EA, van Caubergh RD, De Bruijn WC et al. Morphometry, densitometry and pattern analysis of plastic-embedded histologic material from urothelial cell carcinoma of the bladder. Anal Quant Cytol Histol 1991; 13: 307-15.
57. Albregtsen F, Yogesan K, Nesland JM, Danielsen HE. Prognostic discrimination of mammae cancer using texture analysis. Proceedings of the Norwegian image processing and pattern recognition conference 1992; 1: 248-55. Oslo: Del Norske Radiumhospital, 1992.
58. Decaestecker C, Salmon I, Camby I, Dewitte O, Pasteels J-L, Brotchi J et al. Identification of high versus lower risk clinical subgroups in a group of adult patients with supratentorial anaplastic astrocytomas. J Neuropathol Exp Neurol 1995; 54: 371-84.
59. Narayan P, Michael M, Jajodia P, Stein R, Gonzalez J, Ljung B et al. Automated image analysis - a new technique to predict metastatic potential of prostate carcinomas? J Urol 1989; 141: 183A.
60. Epstein JI, Christensen WN, Steinberg GD, Carter HB. Comparison of dna ploidy and nuclear size, shape and chromatin irregularity in tissue sections and smears of prostatic carcinoma. Anal Quant Cytol Histol 1990; 12: 352-8.
61. Petein M, De Launoit Y, Kiss R, Deprez C, Crols K, Pasteels J-L et al. Characterization of the morphonuclear features and DNA ploidy of prostatic disease. Prostate 1990; 16: 199-208.
62. Armas OA, Pizov G, Pitcock RV, Partin AW, Epstein JI. Nuclear morphology of prostatic carcinoma: comparison of computerized image analysis (CAS 200) versus video planimetry (DynaCELL). Mod Pathol 1991; 4: 763-7.
63. Petein M, Michel P, Van Velthoven R, Pasteels JL, Brawer MK, Davis JR et al. Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. Am J Clin Pathol 1991; 96: 628-34.
64. Wang N, Stenkvist BG, Tribukait B. Morphometry of nuclei of the normal and malignant prostate in relation to DNA ploidy. Anal Quant Cytol Histol 1992; 14: 210-6.
65. Irinopoulou T, Rigaut JP, Benson MC. Toward objective prognostic grading of prostatic carcinoma using image analysis. Anal Quant Cytol Histol 1993; 15: 341-4.
66. Christen R, Xiao J, Minimo C, Gibbons G, Fitzpatrick BT, Galera-Davidson H et al. Chromatin texture features in hematoxylin and eosinstained prostate tissue. Anal Quant Cytol Histol 1993; 15: 383-8.
67. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 1994; 19: 249-58.
68. Aziz DC, Barathur RB. Quantitation and morphometric analysis of tumors by image analysis. J Cell Biochem Suppl 1994; 19: 120-5.
69. Miller J, Horsfall DJ, Skinner JM, Rao DM, Leong AS, Marshall VR. Nuclear shape and prognosis following orchiectomy in stage D2 prostate cancer. Prostate 1994; 24: 306-12.
70. Van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM, Schalken JA. Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. Anal Cell Pathol 1994; 7: 153-70.
71. Petein M, Decaestecker C, Segers V, Janssen T, Fourmarier M, Van Leer P et al. Does any correlation exist between the Gleason classification system and the computer-assisted microscope analysis of Feulgen-stained nuclei features in human prostate adenocarcinoma? Anal Cell Pathol 1996; 12: 159-71.
72. Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. Urology 1996; 48: 685-91.
73. Yogesan K, Jorgensen T, Albregtsen F, Tveler KJ, Danielsen HE. Entropy-based texture analysis of chromatin structure in advanced prostate cancer. Cytometry 1996; 24: 268-76.
74. Jorgensen T, Yogesan K, Tveter KJ, Skjorten F, Danielsen, HE. Nuclear texture analysis: a new prognostic tool in metastatic prostate cancer. Cytometry 1996; 24: 277-83.
75. Veltri RW, O'Dowd GJ, Orozco R, Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin Urol Oncol 1998; 16: 106-17.
76. Mairinger T, Mikuz G, Gschwendtner A. Are nuclear texture features a suitable tool for predicting non-organ-confined prostate cancer? J Urol 1999; 162: 258-62.
77. Mairinger T, Mikuz G, Gschwendtner A. Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. The Prostate 1999; 41: 12-9.
78. Epstein JI, Berry SJ, Eggleston JC. Nuclear roundness factor. A predictor of progression in untreated Stage A2 prostate cancer. Cancer 1984; 54: 1666-71.
79. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 1989; 142: 1254-8.
80. Shaeffer J, Tegeler JA, Kuban DA, Philput CB, el Mahdi AM. Nuclear roundness factor and local failure from definitive radiation therapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 1992; 24: 431-4.
81. Mohler JL, Figlesthaler WM, Zhang X-Z, Partin AW, Maygarden SJ. Nuclear shape analysis for the assessment of local invasion and metastases in clinically localized prostate carcinoma. Cancer 1994; 74: 2996-3001.
82. Jørgensen T, Yogesan K, Skjørten F, Berner A, Tveter KJ, Danielsen HE. Histopathological grading and DNA ploidy as prognostic markers in metastatic prostate cancer. Br J Cancer 1995; 71: 1055-60.
83. Jorgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjorten F et al. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2. J Urol 1997; 158: 164-70.
84. Kayser K, Stute H. Minimum spanning tree, Voronoi's tesselation and Johnson-Mehl diagrams in human lung carcinoma. Pathol Res Pract 1989; 185: 729-34.
85. Bigras G, Marcelpoil R, Brambilla E, Brugal G. Cellular sociology applied to neuroendocrine tumors of the lung: quantitative model of neoplastic architecture. Cytometry 1996; 24: 74-82.
86. Visakorpi T, Kallioniemi A, Syvanen AC, Hyytinen ER, Karhu R, Tammela T et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55: 342-7.
87. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS et al. Genetic alterations in untreated metastases and androgen-independent prostate cancers detected by comparative genomic hybridization and allelotyping. Cancer Res 1996; 56: 3091-4102.
88. Wienberg J, Stanyon R. Chromosome painting in mammals as an approach to comparative genomics. Curr Opin Genet Dev 1995; 5: 792-7.
89. Kanonen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Mod 1998; 4: 767-8.
90. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803-6.